Dennis William Cakouros, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 716 Penllyn Pike, Spring House, PA 19477 Phone: 215-646-1725 |
News Archive
Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.
Midwest Compassion Center and Dr. Alan Shackelford join forces in the fight to treat epilepsy through the use of medical cannabis at their Will County dispensary. With growing concerns over the potentially negative side effects of pharmaceuticals and their inability to provide adequate symptom control in as many as 30% of patients with seizures, Dr. Shackelford and MCC will collaborate on research with the goal of developing new treatment options for patients dealing with a debilitating illness or condition, including seizures.
Recent developments have greatly improved the understanding of the mechanisms used by cells to identify and repair breaks in DNA, and the potential for drugs that target DNA repair in the treatment of a range of human diseases including cancer.
The joint framework for partnership action, announced today by the Health Secretary and the chair of the Disability Rights Commission, will help the NHS to meet the requirements set out in the Disability Discrimination Act.
› Verified 4 days ago